Business / Finance

RSS

New marketplace lender for elective care treatments launched

PrimaHealth Credit, a new marketplace lender for elective healthcare treatments, launched today. The company is transforming how elective care providers and patients access healthcare financing by offering an easy-to-use mobile lending platform and patient friendly, non-punitive financing solutions. PrimaHealth Credit also announced the appointment of industry veteran Hugh Bleemer, the former President of ChaseHealthAdvance, as CEO.

9 Jun 2015

Lycera forms exclusive global collaboration with Celgene

Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the formation of an exclusive global collaboration with Celgene Corporation to take forward Lycera's proprietary pipeline for cancer and immune-mediated diseases.

9 Jun 2015

OncoSec Medical reports net loss of $14.7 million for FY 2015

OncoSec Medical Inc., a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the nine months ended April 30, 2015.

9 Jun 2015

Clarus Ventures announces closure of Clarus Lifesciences III, L.P. and affiliated funds

Clarus Ventures, a leading life science investment firm, announced today the close of Clarus Lifesciences III, L.P. and affiliated funds, a $500 million fund, well above its initial $375 million target.

9 Jun 2015

Molecular Health, TestAnalytika sign distribution agreement for TreatmentMAP in Latin American region

Molecular Health signed an agreement with TestAnalytika to be its preferred distributor in the Latin American region at the 2015 ASCO Annual Meeting. TestAnalytika will begin to market and distribute Molecular Health's cancer treatment decision support product, TreatmentMAP, to patients, physicians, hospitals, laboratories, cancer centers and insurers in Latin America later this year.

8 Jun 2015

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for inflammatory diseases, today announced the successful completion of a $40M Series D financing led by Domain Partners VIII. Additional investors in the financing include Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund.

8 Jun 2015

Merck KGaA, Darmstadt, Germany forms Global Fertility Alliance with Illumina and Genea

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials today announced the formation of the Global Fertility Alliance, a new collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory.

From Illumina, Inc. 8 Jun 2015

Cardinal Health announces plans to acquire The Harvard Drug Group

Cardinal Health today announced plans to acquire The Harvard Drug Group (THDG), a distributor of generic pharmaceuticals, over-the-counter medications and related products to retail, institutional and alternate care customers.

5 Jun 2015

Bio-Techne to acquire 100% ownership of Cliniqa

Bio-Techne Corporation announced today that it has agreed to acquire 100% ownership of Cliniqa Corporation. Cliniqa specializes in the manufacturing and commercialization of quality controls and calibrators as well as bulk reagents used in the clinical diagnostic market.

From CLINIQA - Diagnostics Division 5 Jun 2015

‘Unsurpassed protein SEC’: OMNISEC delivers accurate information with minimal sample

In a new webinar ‘Unsurpassed protein SEC using the latest innovation in advanced detection, OMNISEC’, experts from Malvern Instruments demonstrate how the OMNISEC size exclusion chromatography (SEC) system supports efficient screening early in the drug development pipeline by enabling precise characterization with minimal sample volumes.

5 Jun 2015

Actavis receives FDA approval to market NATRELLE INSPIRA round gel-filled textured breast implants

Actavis plc, which recently completed the acquisition of Allergan, Inc., today announced that the company has received approval from the U.S. Food and Drug Administration to market NATRELLE INSPIRA round gel-filled textured breast implants, offering women undergoing reconstruction, augmentation or revision surgery another breast shaping option for a customized result.

5 Jun 2015

AmpliPhi’s bacteriophage manufacturing facility receives cGMP certification

AmpliPhi’s commissioned its production facility in early 2014 after conducting a comprehensive evaluation of global manufacturing options...

4 Jun 2015

Cyberonics announces results for fourth quarter and fiscal year 2015

Cyberonics, Inc. today announced results for the fourth quarter and fiscal year ended April 24, 2015.

4 Jun 2015

Profil Institute for Clinical Research forms strategic partnership with Gubra

Profil Institute for Clinical Research, an clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today a strategic collaboration with Gubra ApS, a metabolic preclinical and drug discovery company, to combine expertise and resources to discover and translate into clinical research novel drug targets, compounds and biomarkers addressing metabolic disease.

4 Jun 2015

Using technology to protect diabetics from foot amputations: an interview with Heleen Kist, HCi Viocare

When people don’t receive the body’s natural signals due to neuropathy, they can unknowingly be exposing their feet to conditions that are known to cause foot ulcers, such as repeated pressure and shear...

4 Jun 2015

US Equity Holdings announces new funding to launch Aelan Cell Technologies

US Equity Holdings announced yesterday that it has secured funding to launch Aelan Cell Technologies, a biotech startup engaged in the research, discovery, development and commercialization of innovative biomedical technologies and diagnostic tools for the advancement of human health and longevity.

4 Jun 2015

AbbVie selects Halozyme's ENHANZE platform to augment their development pipeline

Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement with AbbVie to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE platform.

3 Jun 2015

Hi-Tech Pharmaceuticals signs definitive agreement to acquire FormuTech Nutrition

Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition products, Contract Manufacturing, and FormuTech Nutrition, one of the fastest-growing Sports Nutrition companies in the United States, today announced that they have entered into a definitive agreement in which Hi-Tech has agreed to acquire FormuTech.

3 Jun 2015

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it has entered into a termination agreement with AstraZeneca, such that all the rights to Ardelyx's portfolio of NHE3 inhibitors, including Ardelyx's lead product candidate, tenapanor, are returned to Ardelyx.

3 Jun 2015

FDA approves Actavis ANDA for guaifenesin/pseudoephedrine tablets to relieve chest congestion

Actavis plc and its partner Perrigo Company plc announced today that Actavis has received U.S. Food and Drug Administration approval for its Abbreviated New Drug Application for guaifenesin/pseudoephedrine tablets and that Perrigo will begin shipments in time for the cough/cold season to its retail and wholesale customers in the U.S. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex® D tablets.

2 Jun 2015

Business / Finance

New marketplace lender for elective care treatments launched

Lycera forms exclusive global collaboration with Celgene

OncoSec Medical reports net loss of $14.7 million for FY 2015

Clarus Ventures announces closure of Clarus Lifesciences III, L.P. and affiliated funds

Molecular Health, TestAnalytika sign distribution agreement for TreatmentMAP in Latin American region

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Merck KGaA, Darmstadt, Germany forms Global Fertility Alliance with Illumina and Genea

Cardinal Health announces plans to acquire The Harvard Drug Group

Bio-Techne to acquire 100% ownership of Cliniqa

‘Unsurpassed protein SEC’: OMNISEC delivers accurate information with minimal sample

Actavis receives FDA approval to market NATRELLE INSPIRA round gel-filled textured breast implants

AmpliPhi’s bacteriophage manufacturing facility receives cGMP certification

Cyberonics announces results for fourth quarter and fiscal year 2015

Profil Institute for Clinical Research forms strategic partnership with Gubra

Using technology to protect diabetics from foot amputations: an interview with Heleen Kist, HCi Viocare

US Equity Holdings announces new funding to launch Aelan Cell Technologies

AbbVie selects Halozyme's ENHANZE platform to augment their development pipeline

Hi-Tech Pharmaceuticals signs definitive agreement to acquire FormuTech Nutrition

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

FDA approves Actavis ANDA for guaifenesin/pseudoephedrine tablets to relieve chest congestion

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News